FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
nours per respons	e 0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Kesponse	.5)														
1. Name and Address of Reporting Person * MARIO ERNEST			2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306				3. Date of Earliest Transaction (Month/Day/Year) 05/12/2016											clow)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person From filed by More then One Reporting Person					
ORK, NY I	(State)	(Zip)		т.	LI. T. N	J T	D								
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	1 2A. Deemed Execution Date, if		3. Transact					5. Amount of Securities			6. 7 Ownership o	'. Nature of Indirect Beneficial	
			(Month/I	Month/Day/Year)		e	V Amount (D) Price		(Instr. 3 and 4)			Ownership (Instr. 4)			
Stock, \$0.	001 par	05/12/2016			P		3	31,042	A	~	380,724	ŀ		D	
Report on a	separate line	for each class of sec	urities bei	neficially	owned										
						С	onta	ained i	n this	form ar	e not req	uired to re	spond unl	ess	C 1474 (9- 02)
_											lly Owned	l			
	Date	Execution D any	Code		of		and Expiration Date (Month/Day/Year) US			Amo Und Secu	ount of derlying urities tr. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
							Date	cisable	Expirat	tion Title	Amount or Number of				
	ERNEST (I) NIX PHAR IG CORP., 06 ORK, NY 1 (I) Security 2. Conversion or Exercise Price of Derivative	ERNEST () (First) NIX PHARMACEUTI IG CORP., 509 MAD () (Street) ORK, NY 10022 () (State) Security 2. (State) Conversion or Exercise Price of Derivative (Month/Day	ERNEST () (First) (Middle) NIX PHARMACEUTICALS IG CORP., 509 MADISON AVENUE, (06 (Street) DRK, NY 10022 (7) (State) (Zip) Security 2. Transaction Date (Month/Day/Year) Table II - 1 Conversion or Exercise Price of Derivative (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Airidle) (Ai	ERNEST t) (First) (Middle) (M	ERNEST (b) (First) (Middle) NIX PHARMACEUTICALS IG CORP., 509 MADISON AVENUE, 06 (Street) (Street) (Street) (Street) (State) (State) (Zip) (A. If Amendment (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (A. Deemed (Execution Date, if any (Month/Day/Year) (Month/Day/Year) (A. Deemed (Month/Day/Year) (Month/Day/Year) (A. Deemed (Execution Date, if any (Month/Day/Year) (A. Deemed (Month/Day/Year) (Month/Day/Year) (A. Deemed (Execution Date, if any (Month/Day/Year) (A. Deemed (A. D	Tonix Pharmaceutical (Middle) (SIT PHARMACEUTICALS (GCORP., 509 MADISON AVENUE, 06 (Street) ORK, NY 10022 (State) (State) (Zip) Table 1 - P Security 2. Transaction Date (Month/Day/Year) OSTOCK, \$0.001 par OSTOCK, \$0.001 par OSTOCK, \$0.001 par Table II - Derivative Securities beneficially owned of Conversion or Exercise Price of Derivative Security (Month/Day/Year) Table II - Derivative Securities beneficially owned on Code (Month/Day/Year) A Security Table II - Derivative Securities beneficially owned on Code (Month/Day/Year) (Month/Day/Year) A Deemed Execution Date, if Code (Instr. S) Execution Date, if Transaction of Code (Price of Derivative Security) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) OSTOCK Table II - Derivative Securities Deneficially owned on Code (Instr. S) OSTOCK OSTOCK (Month/Day/Year) OSTOCK OSTO	Tonix Pharmaceuticals Howard (Middle) (Middle) (Middle) (Mix PHARMACEUTICALS) (Middle) (Mix PHARMACEUTICALS) (Middle) (Middle) (Mix PHARMACEUTICALS) (Middle) (Middle) (Mix PHARMACEUTICALS) (Middle) (Mix PHARMACEUTICALS) (Middle) (Mix Pharmaceuticals Howard (Middle) (Mix Pharmaceuticals Howard (Middle) (Mix Pharmaceuticals Howard (Middle) (Mix Pharmaceuticals Howard (Middle) (Middle) (Mix Pharmaceuticals Howard (Middle)	Table II - Derivative Securities Acquired, Date of Execution Date or Exercise (Month/Day/Year) Table II - Derivative Securities Acquired of Derivative Security Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, doing to the first). Tonix Pharmaceuticals Holding 3. Date of Earliest Transaction (Mo5/12/2016) 3. Date of Earliest Transaction (Mo5/12/2016) Table I - Non-Derivative Securities Transaction (Mo5/12/2016) Table I - Non-Derivative Securities Date of Execution Date, if any (Month/Day/Year) Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 8) Table III - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, doing to the proper of	Tonix Pharmaceuticals Holding Cores (First) (Middle) (MIX PHARMACEUTICALS) (G CORP., 509 MADISON AVENUE, 06 (Street) 4. If Amendment, Date Original Filed(Mont ORK, NY 10022 (Zip) Table 1 - Non-Derivative Security 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (Instr. 3) (Code V Amount Or Exercise (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Persons where the form distribution Date (e.g., puts, calls, warrants, options, conversion or Exercise (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 3) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Disposed of (D) (Instr. 8) (Instr. 8) (Instr. 8) (Month/Day/Year) (Month/Day/Ye	Tonix Pharmaceuticals Holding Corp. [TN 0] (Middle) (STREET) (Month/Day/Year) (Month/	Tonix Pharmaceuticals Holding Corp. [TNXP] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 3. Transaction Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 5. Table I - Non-Derivative Securities Acquired (A) or Disposed of (Instr. 8) 6. A Security (Month/Day/Year) 7. Table II - Derivative Securities Acquired (A) or Disposed of (Disposed of Instr. 8) 8. Transaction Original Filed(Month/Day/Year) 9. A Securities Acquired (A) or Disposed of (Instr. 8) 9. Table II - Derivative Securities Acquired (A) or Disposed of (Disposed of Instr. 8) 1. Transaction Original Filed(Month/Day/Year) 1. Stock, S0.001 par O5/12/2016 1. Stock, \$0.001 par O5/12/2016 1. Stock, \$0.001 par O5/12/2016 2. Transaction Oscillate original Filed(Month/Day/Year) 1. Stock, S0.001 par O5/12/2016 2. Transaction Oscillate original Filed(Month/Day/Year) 2. Transaction Oscillate original Filed(Month/Day/Year) 2. Transaction Oscillate original Filed(Month/Day/Year) 1. Stock, S0.001 par Oscillate original Filed(Month/Day/Year) 2. Transaction Oscillate original Filed(Month/Day/Year) 3. Transaction Oscillate original Filed(Month/Day/Year) 4. Scurities Oscilla	Tonix Pharmaceuticals Holding Corp. [TNXP] (Middle) (Street) (A) (A) (Code (Instr. 3, 4 and 5) (Instr. 3, 4	Tonix Pharmaceuticals Holding Corp. [TNXP] (Chical) (Street) (Street) (Street) (State) (State) (State) (State) (State) (State) (State) (State) (A) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Stock, \$0.001 par (Stock, \$0.001 par (Stock, \$0.001 par (Stock, \$0.001 par (Stock) (Stock) (Stock) (Stock) (Month/Day/Year) (Mont	Tonix Pharmaceuticals Holding Corp. [TNXP] (Check all applic of Corp. [TNXP] (IX) PHARMACEUTICALS (IG CORP., 509 MADISON AVENUE, 06 (Street) (State) (IX) PHARMACEUTICALS (IG CORP., 509 MADISON AVENUE, 06 (State) (IX) PHARMACEUTICALS	Tonix Pharmaceuticals Holding Corp. [TNXP] (Check all applicable) (Month/Day/Year) (Size of Date (Month/Day/Year) (Month/Day/Year) (Size of Date (Month/Day/Year) (Month/Day/Year) (Size of Date (Month/Day/Year) (Month/D

Signatures

MARIO ERNEST

NEW YORK, NY 10022

/s/ Jessica Morris, Attorney-in-Fact	05/12/2016
**Signature of Reporting Person	Date

Reporting Owner Name / Address

C/O TONIX PHARMACEUTICALS HOLDING CORP.

Explanation of Responses:

509 MADISON AVENUE, SUITE 306

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of
- (1) \$2.298749. The range of purchase prices on the transaction date was \$2.285 to \$2.30 per share. The reporting person undertakes to provide, upon request by the SEC staff,

Relationships

10% Owner

Officer

Other

Director

X

the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.